Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 11:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Capsaicin Patch Clear all
Not yet recruiting Phase 4 Interventional

Modality Choice Before and After Failure for the Treatment of Painful Diabetic Neuropathy

NCT07795593
View directory record Official record
Conditions
Painful Diabetic Neuropathy (PDN), Diabetic Nephropathies
Interventions
Cognitive Behavioral Therapy (CBT), Oral Medication, Topical Medication
Device · Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
23
States / cities
Stanford, California • Jacksonville, Florida • Chicago, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 6, 2026, 11:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Lidocaine Patch on Intradermal Capsaicin Induced Pain and Hyperalgesia

NCT00373893
View directory record Official record
Conditions
Pain, Hyperalgesia
Interventions
Lidoderm Patch
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2006 · Synced Sep 6, 2026, 11:06 AM EDT
Terminated Phase 3 Interventional

Study of NGX-4010 for Treatment of Painful HIV-Associated Neuropathy

NCT00085761
View directory record Official record
Conditions
HIV Infections, Peripheral Nervous System Diseases, Pain
Interventions
Capsaicin Dermal Patch
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Sarasota, Florida • Annandale, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 5, 2008 · Synced Sep 6, 2026, 11:06 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Exploring Sympathetic Nervous System Function in Individuals With Down Syndrome

NCT07238465
View directory record Official record
Conditions
Down Syndrome, Autonomic Dysfunction
Interventions
Fear Response, Cold Stress, Pain Response, Caffeine, 12-Hour Fast, Maximal Dynamic Exercise
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 50 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 6, 2026, 11:06 AM EDT
Completed Phase 3 Interventional

Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy

NCT00064623
View directory record Official record
Conditions
HIV Infections, Peripheral Nervous System Diseases, Pain
Interventions
Capsaicin Dermal Patch
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
35
States / cities
Phoenix, Arizona • Berkeley, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2008 · Synced Sep 6, 2026, 11:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effect of Bariatric Surgery on Peripheral Nerve Function and Axonal Regeneration

NCT02218866
View directory record Official record
Conditions
Peripheral Neuropathy, Obesity
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 80 Years
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Sep 6, 2026, 11:06 AM EDT
Completed Phase 2 Interventional

Pilot Study of High-Dose Capsaicin Patches to Treat Postherpetic Neuralgia Pain

NCT00034710
View directory record Official record
Conditions
Neuralgia, Pain, Peripheral Nervous System Diseases, Herpes Zoster
Interventions
Capsaicin Patch
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
8
States / cities
Phoenix, Arizona • Tucson, Arizona • Naples, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2006 · Synced Sep 6, 2026, 11:06 AM EDT
Completed Phase 3 Interventional

Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia

NCT00068081
View directory record Official record
Conditions
Herpes Zoster, Neuralgia, Pain, Peripheral Nervous System Diseases
Interventions
Capsaicin Dermal Patch
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
19
States / cities
Mesa, Arizona • Peoria, Arizona • Phoenix, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2008 · Synced Sep 6, 2026, 11:06 AM EDT
Completed Phase 2 Interventional Results available

The Qutenza Patch as Treatment for Disabling Treprostinil (Remodulin) Infusion Site Pain

NCT01260454
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions
Qutenza (8% capsaicin)
Drug
Lead sponsor
University of Rochester
Other
Eligibility
15 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2016 · Synced Sep 6, 2026, 11:06 AM EDT
Completed Phase 2Phase 3 Interventional

NGX-4010 for the Treatment of Postherpetic Neuralgia

NCT00061776
View directory record Official record
Conditions
Herpes Zoster, Neuralgia, Pain, Peripheral Nervous System Diseases, Shingles
Interventions
Capsaicin Dermal Patch
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
28
States / cities
Huntsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2008 · Synced Sep 6, 2026, 11:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Spinal and Supra-Spinal Pain Mechanisms in Patients With Fibromyalgia

NCT03464292
View directory record Official record
Conditions
Fibromyalgia, Pain
Interventions
Capsaicin Patch 8% or 0.1% Capsaicin Cream, Vehicle Patch
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Sep 6, 2026, 11:06 AM EDT
Completed Phase 1 Interventional

A Study to Compare Levels of Capsaicin After Intra-Articular Injection and Topical Application in Patients With Painful Knee Osteoarthritis

NCT03576508
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
CNTX-4975-05, Qutenza, Lidocaine (without epinephrine)
Drug
Lead sponsor
Centrexion Therapeutics
Industry
Eligibility
50 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Sep 6, 2026, 11:06 AM EDT
Not listed Phase 2 Interventional

Pilot Study of High-Concentration Capsaicin Patches in the Treatment of Painful HIV-Associated Neuropathy

NCT00061152
View directory record Official record
Conditions
HIV Infections
Interventions
Capsaicin Dermal Patch
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
West Hollywood, California • New York, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 13, 2007 · Synced Sep 6, 2026, 11:06 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of a Single Application of Capsaicin 8%Transdermal Delivery System Compared to Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN)

NCT01533428
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy, Pain
Interventions
Capsaicin 8%, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
29
States / cities
Anniston, Alabama • Fresno, California • Long Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Sep 6, 2026, 11:06 AM EDT
Completed Phase 2 Interventional Results available

Do Treatments for Smoking Cessation Affect Alcohol Drinking? Study 1: Nicotine Replacement Therapy

NCT00699556
View directory record Official record
Conditions
Alcohol Drinking
Interventions
21mg transdermal nicotine patch (Nicoderm CQ), 1mg nicotine nasal spray, placebo nasal spray
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 11, 2018 · Synced Sep 6, 2026, 11:06 AM EDT
Recruiting Early Phase 1 Interventional

Exploring the Benefit of Topical Capsaicin in Treating Pain From Chemo-induced Peripheral Neuropathy: a Longitudinal Single Center Pilot Study

NCT06744816
View directory record Official record
Conditions
Peripheral Neuropathy Due to Chemotherapy
Interventions
Qutenza Patch
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 6, 2026, 11:06 AM EDT
Completed Phase 4 Interventional Results available

FS-67 in the Treatment of Pediatric Patients With Ankle Sprain

NCT01037816
View directory record Official record
Conditions
Ankle Sprain
Interventions
FS-67 Patch, Placebo Patch
Drug · Other
Lead sponsor
Hisamitsu Pharmaceutical Co., Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
23
States / cities
Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Sep 6, 2026, 11:06 AM EDT
Withdrawn Phase 2 Interventional

Trial to Evaluate the Efficacy of Topical Capsaicin to Reduce Pain and Improve Health-related Quality of Life in Adults With Chronic Myofascial Neck Pain

NCT00795106
View directory record Official record
Conditions
Myofascial Pain Syndrome
Interventions
Capsaicin, Placebo
Drug
Lead sponsor
Stamford Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Sep 6, 2026, 11:06 AM EDT
Completed Phase 2 Interventional

Tolerability of Three Local Anesthetic Formulations in Conjunction With NGX-4010 for the Treatment of Neuropathic Pain

NCT00082316
View directory record Official record
Conditions
Herpes Zoster, Neuralgia, Pain, HIV Infections, Peripheral Nervous System Diseases, Diabetic Neuropathies, Diabetes Mellitus, Polyneuropathies
Interventions
Capsaicin Dermal Patch
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
17
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2008 · Synced Sep 6, 2026, 11:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Capsaicin 8% Patch for Spinal Cord Injury Neuropathic Pain

NCT02441660
View directory record Official record
Conditions
Spinal Cord Injuries, Neuropathic Pain
Interventions
Capsaicin 8% Patch, Low Dose Capsaicin 0.025% Well Patch
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 99 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Sep 6, 2026, 11:06 AM EDT
Completed Phase 2 Interventional

Study of NGX-4010 With the Use of Open Label Lidocaine (2.5%)/Prilocaine (2.5%) Cream for the Treatment of Postherpetic Neuralgia (PHN)

NCT00916942
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
capsaicin 8%, Lidocaine (2.5%)/Prilocaine (2.5%) Cream
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
6
States / cities
Naples, Florida • St. Petersburg, Florida • Marietta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2009 · Synced Sep 6, 2026, 11:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Clinical Adhesion Study Between ZTlido 1.8% and Three Over-the-counter External Analgesic Lidocaine-containing Patches

NCT05106400
View directory record Official record
Conditions
Healthy
Interventions
ZTlido (Lidocaine Topical System) 1.8%, Salonpas (Lidocaine Patch 4%), Aspercreme (Lidocaine Patch 4%), IcyHot (Lidocaine 4% + Menthol 1% Patch)
Drug
Lead sponsor
Scilex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Dilworth, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Sep 6, 2026, 11:06 AM EDT